|AHFS/Drugs.com||International Drug Names|
|Biological half-life||28 ± 7 hours|
|Chemical and physical data|
|Molar mass||235.07 g/mol|
|3D model (JSmol)|
Pamidronic acid (INN) or pamidronate disodium (USAN), pamidronate disodium pentahydrate (marketed as Aredia by Novartis and as Pamimed by Curacell Biotech), is a nitrogen-containing bisphosphonate used to prevent osteoporosis.
It is used to prevent bone loss, and treat osteoporosis. It is also used to strengthen bone in Paget's disease, to prevent bone loss due to steroid use, and in certain cancers with high propensity to bone, such as multiple myeloma. Due to its ability to sequester calcium in bone, it is also used to treat high calcium levels. It is also used as an experimental treatment of the bone disorder osteogenesis imperfecta. It has been studied in the treatment of complex regional pain syndrome.
Common side effects include bone pain, low calcium levels, nausea, and dizziness. Osteonecrosis of the jaw is a rare complication which has been associated with the use of bisphosphonates, including pamidronate.
- I. Kubalek; O. Fain; J. Paries; A. Kettaneh; M. Thomas (2001). "Treatment of reflex sympathetic dystrophy with pamidronate: 29 cases". Rheumatology. 40 (12): 1394–1397. doi:10.1093/rheumatology/40.12.1394. PMID 11752511.
- Zarychanski R, Elphee E, Walton P, Johnston J (2006). "Osteonecrosis of the jaw associated with pamidronate therapy". Am J Hematol. 81 (1): 73–5. doi:10.1002/ajh.20481. PMID 16369966.
|This drug article relating to the musculoskeletal system is a stub. You can help Wikipedia by expanding it.|